- > About Us
- > CSR (Corporate Social Responsibility)
- > CSR Activities in Six Priority Areas
- > Improving Access to Healthcare
- > Access to Healthcare policy of Daiichi Sankyo Group
Access to Healthcare policy of Daiichi Sankyo Group
The goal of pharmaceutical companies is to act for the benefit of patients and their families by creating pharmaceuticals to respond to the various medical needs seen around the world.
At the Daiichi Sankyo Group, our mission is “to contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs.” Seeking to accomplish this mission, the Daiichi Sankyo Group utilizes various internal capital such as human capital, intellectual capital, financial capital, and social and relationship capital through partnerships and open innovation to take advantage of its strengths in terms of science and technology, its global organization and talent, and firm presence in Japan in order to advance its business activities and thereby contributing to the evolution of society.
Pharmaceutical companies have the various challenges of access to healthcare to be addressed such as the unmet medical needs, access barriers to essential healthcare caused by social factors such as public health, education and income inequality.
The Daiichi Sankyo Group works to address access to healthcare across its entire value chain, which spans everything from research and development to manufacturing, sales & marketing, and quality & safety management, and prioritizes the following three areas: Research and Development, Availability, and Capacity Building.
Research & Development
The Daiichi Sankyo Group leverages the research and development capabilities that have been honed over our years of operating as a drug discovery-oriented company to continually create innovative pharmaceuticals that improve upon current standard of care disease management and thereby develop a business that helps improve patient health.
To quickly adopt the countless findings created worldwide and to meet various medical needs appropriately, the Daiichi Sankyo Group establishes and fosters the partnerships for new drug discovery and technology through many approaches for expansion of external networks and securement of various innovation sources and promotes to merge a diverse range of perspectives into its drug discovery research efforts.
Through our research and development capabilities and partnership engagements, the Daiichi Sankyo Group aims to help address unmet medical needs pertaining to malaria, tuberculosis, neglected tropical diseases in developing countries, and other diseases for which issues regarding access to healthcare are faced in developed or developing countries such as cancer and other non-communicable diseases and rare diseases.
Pharmaceutical products only have meaning as medicine if they can be delivered to patients, and if these patients are able to use them properly. It is recognized that there are many patients with insufficient access to pharmaceuticals due to inadequate supply chains or counterfeit medicines in developing countries and issues with healthcare systems or other factors not only limited to developing countries, but throughout many regions in the world. While considering the economic and market conditions in each country/region, the Daiichi Sankyo Group approaches and works together with various organizations with the aim of improving availability of pharmaceuticals.
The various obstacles impeding access to healthcare in developing countries include,1) the relative lack of healthcare systems and infrastructure, 2) shortages of healthcare professionals, 3) shortages of human capital capable of manufacturing pharmaceuticals, and 4) effectively managing quality control. The Daiichi Sankyo Group will fully leverage its resources with the aim of becoming a positive force toward removing these obstacles.